Miacalcin

Hypercalcemia, Osteoporotic Fractures, Osteoporosis + 5 more

Treatment

20 Active Studies for Miacalcin

What is Miacalcin

Salmon calcitonin

The Generic name of this drug

Treatment Summary

A synthetic nasal spray made up of 32 amino acids.

Miacalcin

is the brand name

Miacalcin Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Miacalcin

Salmon calcitonin

1986

16

Effectiveness

How Miacalcin Affects Patients

Calcitonin stops the breakdown of bones by osteoclasts and helps build up new bone cells. This increases the overall amount of bone in the body and lowers the amount of calcium in the blood. It also helps the kidneys flush out other ions like phosphate, sodium, magnesium, and potassium, which leads to increased water, sodium, potassium, and chloride secretion in the small intestine.

How Miacalcin works in the body

Calcitonin helps to increase bone density by binding to receptors found in osteoclasts. This binding activates enzymes that help the body absorb and retain calcium. It also triggers pathways in the body that help increase bone density.

When to interrupt dosage

The suggested dosage of Miacalcin is contingent upon the determined condition, such as Osteoporosis, Postmenopause and Hypercalcemia. The measurement of dosage shifts, in accordance with the technique of delivery (e.g. Injection, solution or Intramuscular; Subcutaneous) as highlighted in the table below.

Condition

Dosage

Administration

Immobilization

, 200.0 [iU], 2200.0 [iU]/mL, 20000.0 [iU]/mL, 200.0 [iU]/mL, 100.0 [iU], 200.0 [USP'U]/mL, 200.0 units/mL, 200.0 units/pump actuation, 100.0 units/mL, 200.0 units/spray

, Nasal, Spray, metered, Spray, metered - Nasal, Intramuscular; Subcutaneous, Solution - Intramuscular; Subcutaneous, Solution, Liquid, Liquid - Intramuscular; Subcutaneous, Spray, Spray - Nasal, Solution - Nasal, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Injection, solution, Intramuscular, Liquid - Intramuscular; Intravenous; Subcutaneous, Intramuscular; Intravenous; Subcutaneous, Injection, solution - Intramuscular; Subcutaneous, Injection, solution - Intramuscular, Liquid - Nasal

Postmenopause

, 200.0 [iU], 2200.0 [iU]/mL, 20000.0 [iU]/mL, 200.0 [iU]/mL, 100.0 [iU], 200.0 [USP'U]/mL, 200.0 units/mL, 200.0 units/pump actuation, 100.0 units/mL, 200.0 units/spray

, Nasal, Spray, metered, Spray, metered - Nasal, Intramuscular; Subcutaneous, Solution - Intramuscular; Subcutaneous, Solution, Liquid, Liquid - Intramuscular; Subcutaneous, Spray, Spray - Nasal, Solution - Nasal, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Injection, solution, Intramuscular, Liquid - Intramuscular; Intravenous; Subcutaneous, Intramuscular; Intravenous; Subcutaneous, Injection, solution - Intramuscular; Subcutaneous, Injection, solution - Intramuscular, Liquid - Nasal

Paget’s Disease

, 200.0 [iU], 2200.0 [iU]/mL, 20000.0 [iU]/mL, 200.0 [iU]/mL, 100.0 [iU], 200.0 [USP'U]/mL, 200.0 units/mL, 200.0 units/pump actuation, 100.0 units/mL, 200.0 units/spray

, Nasal, Spray, metered, Spray, metered - Nasal, Intramuscular; Subcutaneous, Solution - Intramuscular; Subcutaneous, Solution, Liquid, Liquid - Intramuscular; Subcutaneous, Spray, Spray - Nasal, Solution - Nasal, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Injection, solution, Intramuscular, Liquid - Intramuscular; Intravenous; Subcutaneous, Intramuscular; Intravenous; Subcutaneous, Injection, solution - Intramuscular; Subcutaneous, Injection, solution - Intramuscular, Liquid - Nasal

Hypercalcemia

, 200.0 [iU], 2200.0 [iU]/mL, 20000.0 [iU]/mL, 200.0 [iU]/mL, 100.0 [iU], 200.0 [USP'U]/mL, 200.0 units/mL, 200.0 units/pump actuation, 100.0 units/mL, 200.0 units/spray

, Nasal, Spray, metered, Spray, metered - Nasal, Intramuscular; Subcutaneous, Solution - Intramuscular; Subcutaneous, Solution, Liquid, Liquid - Intramuscular; Subcutaneous, Spray, Spray - Nasal, Solution - Nasal, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Injection, solution, Intramuscular, Liquid - Intramuscular; Intravenous; Subcutaneous, Intramuscular; Intravenous; Subcutaneous, Injection, solution - Intramuscular; Subcutaneous, Injection, solution - Intramuscular, Liquid - Nasal

Osteoporotic Fractures

, 200.0 [iU], 2200.0 [iU]/mL, 20000.0 [iU]/mL, 200.0 [iU]/mL, 100.0 [iU], 200.0 [USP'U]/mL, 200.0 units/mL, 200.0 units/pump actuation, 100.0 units/mL, 200.0 units/spray

, Nasal, Spray, metered, Spray, metered - Nasal, Intramuscular; Subcutaneous, Solution - Intramuscular; Subcutaneous, Solution, Liquid, Liquid - Intramuscular; Subcutaneous, Spray, Spray - Nasal, Solution - Nasal, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Injection, solution, Intramuscular, Liquid - Intramuscular; Intravenous; Subcutaneous, Intramuscular; Intravenous; Subcutaneous, Injection, solution - Intramuscular; Subcutaneous, Injection, solution - Intramuscular, Liquid - Nasal

Osteoporosis

, 200.0 [iU], 2200.0 [iU]/mL, 20000.0 [iU]/mL, 200.0 [iU]/mL, 100.0 [iU], 200.0 [USP'U]/mL, 200.0 units/mL, 200.0 units/pump actuation, 100.0 units/mL, 200.0 units/spray

, Nasal, Spray, metered, Spray, metered - Nasal, Intramuscular; Subcutaneous, Solution - Intramuscular; Subcutaneous, Solution, Liquid, Liquid - Intramuscular; Subcutaneous, Spray, Spray - Nasal, Solution - Nasal, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Injection, solution, Intramuscular, Liquid - Intramuscular; Intravenous; Subcutaneous, Intramuscular; Intravenous; Subcutaneous, Injection, solution - Intramuscular; Subcutaneous, Injection, solution - Intramuscular, Liquid - Nasal

Osteitis Deformans

, 200.0 [iU], 2200.0 [iU]/mL, 20000.0 [iU]/mL, 200.0 [iU]/mL, 100.0 [iU], 200.0 [USP'U]/mL, 200.0 units/mL, 200.0 units/pump actuation, 100.0 units/mL, 200.0 units/spray

, Nasal, Spray, metered, Spray, metered - Nasal, Intramuscular; Subcutaneous, Solution - Intramuscular; Subcutaneous, Solution, Liquid, Liquid - Intramuscular; Subcutaneous, Spray, Spray - Nasal, Solution - Nasal, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Injection, solution, Intramuscular, Liquid - Intramuscular; Intravenous; Subcutaneous, Intramuscular; Intravenous; Subcutaneous, Injection, solution - Intramuscular; Subcutaneous, Injection, solution - Intramuscular, Liquid - Nasal

Therapeutic procedure

, 200.0 [iU], 2200.0 [iU]/mL, 20000.0 [iU]/mL, 200.0 [iU]/mL, 100.0 [iU], 200.0 [USP'U]/mL, 200.0 units/mL, 200.0 units/pump actuation, 100.0 units/mL, 200.0 units/spray

, Nasal, Spray, metered, Spray, metered - Nasal, Intramuscular; Subcutaneous, Solution - Intramuscular; Subcutaneous, Solution, Liquid, Liquid - Intramuscular; Subcutaneous, Spray, Spray - Nasal, Solution - Nasal, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Injection, solution, Intramuscular, Liquid - Intramuscular; Intravenous; Subcutaneous, Intramuscular; Intravenous; Subcutaneous, Injection, solution - Intramuscular; Subcutaneous, Injection, solution - Intramuscular, Liquid - Nasal

Warnings

There are 20 known major drug interactions with Miacalcin.

Common Miacalcin Drug Interactions

Drug Name

Risk Level

Description

Abacavir

Minor

Salmon calcitonin may decrease the excretion rate of Abacavir which could result in a higher serum level.

Acetaminophen

Minor

Salmon calcitonin may decrease the excretion rate of Acetaminophen which could result in a higher serum level.

Acetohexamide

Minor

The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Salmon calcitonin.

Aclidinium

Minor

Salmon calcitonin may decrease the excretion rate of Aclidinium which could result in a higher serum level.

Acrivastine

Minor

Salmon calcitonin may decrease the excretion rate of Acrivastine which could result in a higher serum level.

Miacalcin Toxicity & Overdose Risk

Salmon calcitonin is not recommended for nursing mothers, as it has been linked to decreased fetal weight in animals. It is important to weigh the pros and cons when administering salmon calcitonin to pregnant women. In addition, salmon calcitonin can cause allergic reactions, including swelling of the tongue or throat, and an increased risk in malignancies. Other side effects include nausea, rhinitis, headaches, and back pain.

image of a doctor in a lab doing drug, clinical research

Miacalcin Novel Uses: Which Conditions Have a Clinical Trial Featuring Miacalcin?

57 active clinical trials are in progress to examine the possibility of using Miacalcin to facilitate Therapeutic procedures, Postmenopausal states and Osteitis Deformans.

Condition

Clinical Trials

Trial Phases

Hypercalcemia

1 Actively Recruiting

Phase 4

Immobilization

0 Actively Recruiting

Paget’s Disease

0 Actively Recruiting

Osteoporotic Fractures

3 Actively Recruiting

Phase 4, Not Applicable

Osteoporosis

28 Actively Recruiting

Not Applicable, Phase 4, Phase 1, Phase 3, Phase 2

Osteitis Deformans

0 Actively Recruiting

Postmenopause

6 Actively Recruiting

Phase 2, Not Applicable

Therapeutic procedure

0 Actively Recruiting

Miacalcin Reviews: What are patients saying about Miacalcin?

5

Patient Review

11/14/2007

Miacalcin for Decreased Bone Mass Following Menopause

I've been using Miacalcin for a while now, and it's easy to use but slow-acting. My bone density test showed that I was losing bone mass, so now I take it in combination with Boniva.

5

Patient Review

2/28/2008

Miacalcin for Decreased Bone Mass Following Menopause

This medication has increased my bone density, and I've been using it for a while now without any issues.

5

Patient Review

6/18/2010

Miacalcin for Decreased Bone Mass Following Menopause

Miacalcin was working great for me, but since my insurance company raised the price beyond what I can afford, I've experienced a significant amount of bone loss.

5

Patient Review

6/22/2009

Miacalcin for Decreased Bone Mass Following Menopause

Miacalcin not only improved the results on my spine, but has kept my readings from my hip bone stable for the past three years.

4.7

Patient Review

4/4/2009

Miacalcin for Decreased Bone Mass Following Menopause

I had no issues taking this medication, and it didn't come with any unwanted side effects. However, after a year of use my bone density test did not show any improvement.

4

Patient Review

10/7/2008

Miacalcin for Decreased Bone Mass Following Menopause

This treatment has been easy to use and I haven't had any negative side effects so far. My next bone scan will give more information.

4

Patient Review

9/18/2007

Miacalcin for Decreased Bone Mass Following Menopause

3.7

Patient Review

9/29/2009

Miacalcin for Decreased Bone Mass Following Menopause

Easy enough to use - I just put the bottle in the cabinet on whichever side I used it that day, so I know to switch sides tomorrow. The only problem is that I've started losing hair since using this medication and don't know if it's related.

3

Patient Review

3/2/2010

Miacalcin for Decreased Bone Mass Following Menopause

I've been using this treatment for four years to help with osteoperosis. While there has been some improvement in my bone mass, it's only been slight. I also experienced a lot of nosebleeds and redness on the top of my nose while using this product. Thankfully, those side effects have gone away since discontinuing use six weeks ago.

3

Patient Review

3/16/2010

Miacalcin for Osteoporosis

This treatment really helped me. I'm grateful for modern medicine.

3

Patient Review

10/26/2007

Miacalcin for Decreased Bone Mass Following Menopause

I'm optimistic about this treatment.

2.3

Patient Review

12/3/2008

Miacalcin for Decreased Bone Mass Following Menopause

I had no problems using this for about a year, but now I sneeze uncontrollably whenever I use it. Additionally, I experienced unexplained back pain that has since gone away after discontinuing use. However, my bone density did improve while taking Miacalcin with Evista, so I'm not happy that I can't use it anymore. There is also a generic Fortical available.

1

Patient Review

2/3/2014

Miacalcin for Decreased Bone Mass Following Menopause

I was taking calcitonin salmon for a couple of years before my drug supplier changed and started sending me Miacalin instead. It smells disgustingly, like old garbage. Even with the previous medication I was getting daily headaches and sinus pain. My doctor encouraged me to keep using it but the side effects are not worth it to me.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about miacalcin

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Miacalcin made from salmon?

"Miacalcin is a hormone that is found naturally in the thyroid gland. It is used to treat Paget's disease of bone, postmenopausal osteoporosis, or high levels of calcium in the blood (hypercalcemia)."

Answered by AI

Is Miacalcin effective with osteoporosis?

"Miacalcin injection can help treat osteoporosis in postmenopausal women who are more than 5 years past menopause. The evidence that it works comes from trials where people taking the injection had increases in the amount of calcium in their bodies. However, it has not been shown to help reduce fractures."

Answered by AI

What kind of drug is Miacalcin?

"Calcitonin is a medication that comes in the form of a nasal spray or injection. It is used to treat osteoporosis in postmenopausal females, Paget's disease of bone, and high calcium. Although it is available in a generic form, it is not typically the first choice for treatment."

Answered by AI

What is Miacalcin used for?

"This medication is used to treat certain bone problems, such as Paget's disease, postmenopausal osteoporosis, by reducing high blood levels of calcium. Calcitonin, a man-made hormone, works by slowing bone loss and maintaining normal calcium levels in the blood."

Answered by AI

Clinical Trials for Miacalcin

Image of Translational Physiology Laboratory within the Food Science Clinical Research Laboratory in Fort Collins, United States.

Mitoquinone for Postmenopausal Brain Health

18+
Female
Fort Collins, CO

The goal of this clinical trial is to learn if 3 months of taking the dietary supplement MitoQ \[a mitochondria-targeted antioxidant that targets to reduce mitochondrial reactive oxygen species (mitoROS)\] works to treat age- and menopause-related reductions in brain artery (cerebrovascular) function in postmenopausal women 60 years of age or older free of clinical disease. The main questions it aims to answer are: Does MitoQ improve cerebrovascular function in postmenopausal women? If so, does MitoQ improve cerebrovascular function by lowering mitoROS in these arteries? Researchers will compare MitoQ to a placebo (a look-alike substance that contains no drug) to see if MitoQ can improve cerebrovascular function by lowering mitoROS in arteries involved in brain health and function. Participants will: Take MitoQ (20 mg/day) or a placebo every day for 3 months Visit the research laboratory at baseline and then after 3 months for cerebrovascular testing; there is also a check-in visit at 6 weeks, which is the halfway point Keep track of symptoms and events during their treatment period to report to the study team

Waitlist Available
Dietary Supplement

Translational Physiology Laboratory within the Food Science Clinical Research Laboratory

Image of UC San Diego in San Diego, United States.

Epione Device for Bone Conditions

18+
All Sexes
San Diego, CA

The goal of this investigational device exemption is to evaluate the Epione assistance for introducer placement during percutaneous procedures in musculo-skeletic (MSK) structures of the pelvis and the spine in adults. The main question is the determination of the rate of feasible procedures assisted by the Epione device Participants will undergo their procedure(s) as planned by their physician. If they accept to participate to the study, the differences with standard of care will be: * The use of the Epione device to place the introducer(s), instead of freehand placement if they do not participate * Additional CT or CBCT scans during the procedure.

Waitlist Available
Has No Placebo

UC San Diego (+2 Sites)

Sean Tutton, MD

Quantum Surgical

Image of University of Waterloo in Waterloo, Canada.

Virtual Chiropractic Intervention for Spinal Fracture

18+
All Sexes
Waterloo, Canada

This study will determine feasibility of a chiropractor delivered virtual intervention for individuals following osteoporotic vertebral fracture. This pilot trial will have two parallel groups with a 1:1 ratio. Participants will be randomized to: 1) immediate receipt; or 2) waitlist usual care control and delayed receipt of VIVA 10 weeks post-randomization. VIVA is an intervention for people with vertebral fractures that covers four areas: pain management, safe movement, exercise, and nutrition. It includes print and video resources, and a framework for goal setting, selecting exercises, and teaching body mechanics. A chiropractor (DC) completes a virtual assessment and then leads twelve 1:1 virtual sessions (via Zoom) over eight weeks. Sessions start with brief education on a topic (e.g., safe movement, pain management, exercise, nutrition), followed by training and modeling of exercise and safe movement strategies, then goal setting, and action planning. This trial will be considered feasible if a) we recruit 14 people in eight months; b) 80% of participants complete the trial; and c) exercise adherence is 75%.

Recruiting
Has No Placebo

University of Waterloo

Have you considered Miacalcin clinical trials?

We made a collection of clinical trials featuring Miacalcin, we think they might fit your search criteria.
Go to Trials
Image of Don tyson Center for Agricultural Sciencers in Fayetteville, United States.

Protein and Exercise for Postmenopausal Women

Any Age
Female
Fayetteville, AR

The goal of this clinical trial is to learn if consuming a higher protein diet that includes one serving of beef each day, in combination with resistance exercise, improves wellbeing in postmenopausal women. It will also tell us about how higher protein intake changes body composition and blood values related to health. The main questions it aims to answer are: * Does higher protein intake combined with resistance training improve mood and sleep in postmenopausal women? * What other health benefits to postmenopausal women experience when the follow a higher protein diet and participate in resistance exercise? Researchers will compare three groups 1) postmenopausal women living their daily lives as usual, 2) postmenopausal women consuming a higher protein diet, and 2) postmenopausal women consuming a higher protein diet and participating in resistance training. Participants will: * Consume a higher protein diet for 16 weeks * Participate in an at-home resistance training for 16 weeks * Keep a diary of their food intake, sleep habits, and mood * Have health assessments every 4 weeks

Recruiting
Has No Placebo

Don tyson Center for Agricultural Sciencers (+1 Sites)

Jamie Baum

Image of The Buck Institute for Research on Aging in Novato, United States.

GLYLO Supplement for Postmenopausal Aging

45 - 65
Female
Novato, CA

The aim of this study is to assess the effectiveness of GLYLO, a dietary supplement, in postmenopausal women aged 45 to 65 who are overweight or obese and have elevated HbA1c levels. Specifically, the study seeks to evaluate whether GLYLO can reduce advanced glycation end products (AGEs) levels, which are harmful compounds formed when sugar attaches to proteins or fats in the body and can contribute to aging and disease. The primary outcome of the study is to determine if GLYLO reduces AGEs, enhances metabolic and hormonal health, and mitigates age-related functional decline. This study includes one screening visit and three testing visits over a 6-month period. After eligibility is confirmed, participants will be randomly assigned to one of two groups to take either GLYLO (two capsules daily) or a placebo at home for 24 weeks. Participants will provide blood samples at every visit. During the three testing visits, they will complete physical performance and cognitive function tests, provide both blood and urine samples, and fill out quality of life and 24-hour dietary intake questionnaires. The dietary intake questionnaires will be completed only twice i.e. at the baseline visit and again at the final 6-month visit.

Recruiting
Advanced

The Buck Institute for Research on Aging

Image of University of Maryland, Baltimore, Department of Epidemiology and Public Health, Division of Gerontology in Baltimore, United States.

OPTIONS Program for Osteoporosis

65+
All Sexes
Baltimore, MD

Osteoporosis is a disease that weakens bones so the bones may break easily. The risk for osteoporosis increases with age in both women and men. Osteoporosis affects 10 million older adults in the US. Osteoporosis is a common cause of broken bones in the hips and legs. Broken bones can lead to disability, nursing home placement, and death. Because of the dire consequences, a broken hip or leg is one of the most dreaded injuries for older adults. Many studies confirm that a simple regimen of exercise, healthy diet and bone-strengthening medications can improve overall recovery after a broken hip or leg. This regimen can prevent a person from becoming disabled, having future fractures, and even prevent death. Many older adults have surgery in a hospital after breaking a hip or leg. Then older adults go to a skilled nursing facility (SNF) for rehabilitation. Care in SNFs varies greatly. Some patients do not receive the regimen that the investigators know is most beneficial to improve bone health and recovery. Even patients who get exercise, healthy diet, and bone-strengthening medication in the SNF, may not continue with the regimen once patients go home. Therefore, the investigators want to implement and test OsteoPorotic fracTure preventION System (OPTIONS). OPTIONS is a program that will integrate the regimen into the care that is provided in SNFs and after discharge to the community. OPTONS will provide information about exercise, diet, and bone-strengthening medication. OPTIONS will provide doctors, clinical staff, patients, and care partners with the information these stakeholders need to carry out the best-practice regimen. The investigators are partnering with PointClickCare, a large cloud-based healthcare software provider, with SNFs and community care sites across the US. The investigators will include 32 SNFs from different US areas. The investigators will flip a coin to assign SNFs to the intervention (OPTIONS) or the control arm (enhanced usual care) of the study. Enhanced usual care is the care that is typically provided in SNFs after a fracture and adding information about a publicly available fall prevention toolkit. The investigators are using an "implementation science" approach that requires the investigators to get input from the OPTIONS study's vast stakeholder community throughout the study. The OPTIONS study's stakeholders include patients, care partners, clinicians, and professional organizations. The research question is, can using OPTIONS in SNFs and in the community after discharge improve physical function and quality of life in older people in the year after a hip or leg fracture? The investigators are measuring patient-reported outcomes. The investigators will include 1553 patients across the 32 facilities. The investigators have selected outcomes that are important to patients. Specifically, the investigators are measuring patient-reported function and quality of life. The investigators are also measuring patient-reported falls and fractures. The investigators will track the number of patients who die during the study. This study's hypothesis is that patients who receive OPTIONS will report better physical function (i.e., can walk and take better care of themselves) than those who receive enhanced usual care. The investigators also hypothesize that patients that receive OPTIONS will report a better quality of life than those who receive enhanced usual care. This study will provide sound data about the effectiveness of OPTIONS. OPTIONS could then be spread to other SNFs and community-based programs. This would ensure that all older people receive the right care after a hip or leg fracture.

Recruiting
Has No Placebo

University of Maryland, Baltimore, Department of Epidemiology and Public Health, Division of Gerontology (+1 Sites)

Denise Orwig, PhD

Have you considered Miacalcin clinical trials?

We made a collection of clinical trials featuring Miacalcin, we think they might fit your search criteria.
Go to Trials

Have you considered Miacalcin clinical trials?

We made a collection of clinical trials featuring Miacalcin, we think they might fit your search criteria.
Go to Trials